Gilead Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Gilead Sciences wird ein jährliches Gewinn- und Umsatzwachstum von 10.5% bzw. 3.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 33% betragen.

Wichtige Informationen

10.5%

Wachstumsrate der Gewinne

10.35%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	23.7%
Wachstumsrate der Einnahmen	3.5%
Zukünftige Eigenkapitalrendite	33.00%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Jun 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gilead Sciences' Best Days May Be Ahead - Here's Why

May 26

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

May 15

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Feb 18

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Feb 11

Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Feb 09

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Feb 03

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Dec 29

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Dec 18

Gilead Sciences, Inc.'s (NASDAQ:GILD) Business And Shares Still Trailing The Industry

Dec 13

We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings

Nov 13

Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year

Nov 07

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Oct 01

Gilead Sciences: Buy This Bargain Before It's Gone

Aug 30

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

Aug 05

A Look At Gilead Sciences After Its Recent Weakness

Jul 27

Gilead Records Positive Phase III Results In HIV

Jun 22

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Jun 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:GILD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2027	31,195	9,146	11,860	11,819	22
12/31/2026	29,720	8,434	11,581	11,291	27
12/31/2025	28,650	7,488	10,663	10,507	27
3/31/2025	28,735	5,965	9,844	10,366	N/A
12/31/2024	28,754	480	10,305	10,828	N/A
9/30/2024	28,299	126	9,431	10,022	N/A
6/30/2024	27,805	1,054	6,896	7,468	N/A
3/31/2024	27,450	485	7,900	8,481	N/A
12/31/2023	27,116	5,665	7,421	8,006	N/A
9/30/2023	27,391	5,876	7,853	8,404	N/A
6/30/2023	27,382	5,484	8,926	9,512	N/A
3/31/2023	27,043	5,583	8,386	8,976	N/A
12/31/2022	27,281	4,592	8,344	9,072	N/A
9/30/2022	27,136	3,334	9,007	9,710	N/A
6/30/2022	27,515	4,137	9,415	10,100	N/A
3/31/2022	27,472	4,515	9,953	10,614	N/A
12/31/2021	27,305	6,225	10,805	11,384	N/A
9/30/2021	27,482	7,394	9,491	10,095	N/A
6/30/2021	26,638	5,162	8,472	9,092	N/A
3/31/2021	25,564	301	8,698	9,342	N/A
12/31/2020	24,689	123	7,518	8,168	N/A
9/30/2020	23,147	1,268	8,160	8,832	N/A
6/30/2020	22,174	-257	8,510	9,227	N/A
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	7,639	8,476	N/A
3/31/2019	22,320	5,892	6,758	7,707	N/A
12/31/2018	22,127	5,455	N/A	8,400	N/A
9/30/2018	22,281	1,587	N/A	8,808	N/A
6/30/2018	23,197	2,208	N/A	9,290	N/A
3/31/2018	24,690	3,464	N/A	11,243	N/A
12/31/2017	26,107	4,628	N/A	11,898	N/A
9/30/2017	27,478	11,601	N/A	12,684	N/A
6/30/2017	28,466	12,213	N/A	14,383	N/A
3/31/2017	29,101	12,637	N/A	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A
9/30/2014	20,696	9,406	N/A	10,524	N/A
6/30/2014	17,437	7,463	N/A	7,233	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GILDDas prognostizierte Gewinnwachstum (10.5% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: GILDDie Erträge des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.5% pro Jahr).

Hohe Wachstumserträge: GILDDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: GILDDie Einnahmen des Unternehmens (3.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.6% pro Jahr).

Hohe Wachstumseinnahmen: GILDDie Einnahmen des Unternehmens (3.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GILDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (33%)

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/06/04 10:48
Aktienkurs zum Tagesende	2025/06/04 00:00
Gewinne	2025/03/31
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Gilead Sciences, Inc. wird von 71 Analysten beobachtet. 27 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
David Toung	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Gilead Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 36%

Price target increased by 7.6% to US$94.62

Consensus EPS estimates fall by 31%, revenue upgraded

Consensus EPS estimates fall by 21%

Recent updates

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences' Best Days May Be Ahead - Here's Why

Chief Commercial Officer notifies of intention to sell stock

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025

Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

First quarter dividend of US$0.79 announced

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 Study

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025

New HIV, Livdelzi And CAR T Options Will Expand Reach

Gilead Sciences, Inc., Annual General Meeting, May 07, 2025

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally

Chairman & CEO exercised options and sold US$1.4m worth of stock

Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Gilead Sciences, Inc. Presents the First Data from Its Ongoing Phase 1 Study Investigating Two Novel, Once-Yearly Formulations of Lenacapavir

Upcoming dividend of US$0.79 per share

Why Gilead Sciences Remains A Buy After A 40% Rally

European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Chief Financial Officer exercised options and sold US$4.8m worth of stock

Fourth quarter dividend increased to US$0.79

New minor risk - Financial position

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Gilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead Sciences, Inc.'s (NASDAQ:GILD) Business And Shares Still Trailing The Industry

Gilead Sciences, Inc. Announces Chief Medical Officer Changes

Consensus EPS estimates fall by 27%

Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition

Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH

Chief Financial Officer exercised options and sold US$5.5m worth of stock

Upcoming dividend of US$0.77 per share

Consensus EPS estimates fall by 36%

Chief Medical Officer recently sold US$1.7m worth of stock

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Price target increased by 7.6% to US$94.62

We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Consensus EPS estimates fall by 31%, revenue upgraded

Third quarter dividend of US$0.77 announced

Chief Medical Officer notifies of intention to sell stock

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference